ClinicalTrials.gg
RecruitingNCT07425574EVOLVEUpdated Nov 13, 2026

A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults

An observational study in Stargardt Disease, Stargardt Macular Dystrophy and Stargardt-like Macular Dystrophy, sponsored by Astellas Pharma Global Development, Inc.. Recruiting at 15 sites in United States. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Oct 20, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
90
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 42 studies in Stargardt Disease with a site in United States — 16 open to participants now, 25 under way, 3 of them phase 3. Stargardt Disease · United States.

Planned enrollment
5th of 16
90 · median 63
Started
2026
with 5 others
Observational
16 of 42
8 open now
Primary completion
2028-12
later than 13 of 24 live
Registered
37th of 42
by date
Lead sponsor
2 of 42
Astellas Pharma Global Development, Inc.

Among the 42 studies in Stargardt Disease with a site in United States, this one is the 5th largest by planned enrollment of the 16 observational ones that give a count, is one of 6 that started in 2026, is one of 16 observational ones, reaches primary completion later than 13 of the 24 other live ones, and was the 37th registered.

Stargardt Disease

68 studies on the registry are indexed under Stargardt Disease; 27 are open to participants now.

Browse Stargardt Disease studies →

Open to participants now

16 of the 42 studies in Stargardt Disease with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Stargardt Disease studies recruiting now, 15 (63%) set no upper age limit and 7 (29%) stop at 75 or younger; 13 take children under 18; 6 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Stargardt Disease with a site in United States, or all of them as a file.
02

Study summary

Macular dystrophies are a group of inherited eye conditions that affect the macula. The macula is in the center of the retina, the light sensitive part at the back of the eye. In people with macular dystrophies, some of the cells in the macula gradually stop working and may die over time. This leads to vision loss in the center of the eye. Side vision (peripheral vision) is mostly unaffected. Stargardt disease (STGD) is a type of macular dystrophy which is caused by 1 faulty gene (ABCA4). Vision loss most typically happens in childhood, but many people do not develop it until they are adults. As well as STGD, there are other macular dystrophies that look very similar to STGD but that are caused by many other different genes. Together, STGD and STGD-like conditions can be called STGD-type macular dystrophies. This is because they look the same clinically and have similar symptoms. Since different genes can cause these conditions, genetic testing is the only way to be sure which specific condition a person has.

In this study, researchers want to learn if the disease progresses in a similar way in people with STGD and STGD-like macular dystrophies. People taking part in the study will continue to manage their condition, as agreed with their own doctor. People will visit their clinic every 6 months to have various standard eye tests and imaging. The information collected will include questions about people's wellbeing, general health, medication and supplements taken, and daily activities.

Children over 6 years old and adults with STGD-type macular dystrophies may take part in this study. They will be in the study for up to 24 months (2 years). The study sponsor (Astellas) will not decide how people's condition is managed. However, the sponsor will provide instructions on when people visit their clinic and what is recorded during the study. If available, medical records, clinical and imaging data from previous visits going back 24 months will also be reviewed.

03

Conditions studied

  • Stargardt Disease
  • Stargardt Macular Dystrophy
  • Stargardt-like Macular Dystrophy

Keywords

  • Macular Dystrophies
  • Stargardt type
  • ABCA4 related STGD
  • STGD-like macular dystrophies
04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants aged ≥ 6 years at baseline with clinically confirmed macular dystrophy of STGD-type clinical presentation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has a documented clinical diagnosis of macular dystrophy expressing a STGD-type clinical presentation and molecular confirmation, defined as either:

    • ABCA4-associated disease: presence of biallelic (pathogenic or likely pathogenic) ABCA4 variants, or one definite disease-causing ABCA4 variant together with a typical phenotype consistent with STGD.
    • STGD-like macular dystrophy: presence of one or more pathogenic variants in a gene known to cause macular dystrophy, as appropriate for its expected inheritance mode. Note: All genetic testing should be performed by a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory or equivalent whenever possible. Acceptable documentation includes a copy of the genetic test report, laboratory certification statement, or clinical notes explicitly referencing CLIA certification. Predicted pathogenic variant of uncertain significance (VUS) that cannot be confirmed by standard laboratory criteria as certainly disease-causing (novel mutations) will be considered on a case by-case basis.
  • Participant has sufficiently clear ocular media and adequate pupillary dilation to allow for all imaging procedures.
  • Participant has intraocular pressure (IOP) both at screening and baseline of ≤ 21 mmHg measured by applanation tonometry. Note: Participant who is on topical IOP lowering treatment may also be included.
  • Participant has a spherical equivalent refractive error between + 8.00 D and - 10.00 D. Eyes with high myopia (> -10.00 D) are permitted only if there are no signs of myopic degenerative macular changes.
  • Participant has a BCVA ranging from 20/500 to 20/40 (equivalent to 15 to 70 ETDRS letters read at 1 meter)

    • For participants in the > 20/80 to ≤ 20/40 BCVA range (moderate visual impairment [MVI]): presence of a visible definite or probable residual EZ on spectral-domain optical coherence tomography (SD-OCT) (no minimum residue size required) and a total retinal SD-OCT central subfield retinal thickness ≥ 150 µm
    • For participants in the ≥ 20/500 to ≤ 20/80 BCVA range (SVI): presence of a residual outer nuclear layer (ONL) within the macular SD-OCT scan area and measurable within the Age-Related Eye Disease Study (AREDS) grading grid and no residual EZ or minimal thickness of the ONL required
  • Participant has evidence of retinal pigment epithelium (RPE) disease/damage on SD-OCT (hypertransmission defects [HTDs]) and/or FAF imaging.
  • Participant has evidence of at least questionably decreased autofluorescence (QDAF) (incomplete retinal pigment epithelial and outer retinal atrophy [iRORA]), defined as mottled or speckled hypo-autofluorescence (AF) signal, mixed with or without hyper- AF, on FAF imaging. Note: At study onset, having patches of definitely decreased autofluorescence (DDAF) within the FAF image and/or patches of complete retinal pigment epithelial and outer retinal atrophy (cRORA) on SD-OCT ≥ 250 µm will not be a requirement for participation but will be acceptable for inclusion, so long as:

    • DDAF/cRORA areas are contained within the limits of the AREDS grading grid (≤ 12 disc areas), and physically distinct and separate from other areas of QDAF, DDAF and/or hyper-AF that may be present outside the AREDS grading grid, and
    • the other BCVA and SD-OCT required inclusion criteria are also met.
  • Participant is able to comply with the protocol and willing to undertake all scheduled visits and assessments during the total study period.
  • Participant is deemed capable of performing reliably all tests required for participation.

Exclusion criteria

Exclusion Criteria:

  • Participant has a known history of significant systemic disease (e.g., uncontrolled hepatitis, pancreatitis, cirrhosis, liver failure, uncontrolled thyroid disease or immunocompromising conditions such as [HIV]) that could impact ocular health or confound study assessments, based on medical history or prior clinical documentation.
  • Participant has an condition that requires treatment with immunomodulatory therapy and/or biologics that cause .
  • Participant has a known diagnosis of diabetes mellitus with a documented (HbA1c) value ≥ 7% 3 months prior to screening and based on available medical records. If the documented HbA1c is ≥ 7% and there is no clinical history of diabetic symptoms, diabetic retinopathy, abnormal renal function (e.g., elevated creatinine), or glycosuria noted in medical records, the participant may be enrolled.
  • Participant has a known history of any systemic or metabolic condition, or physical examination finding that may significantly affect ocular health or interfere with the interpretation of study assessments.
  • Participant has a history or evidence of severe cardiac disease (e.g., Functional Class III or IV), clinical evidence of unstable angina, acute coronary syndrome, myocardial infarction or revascularization within 6 months prior to screening.
  • Participant has a history or evidence of ventricular tachyarrhythmia requiring ongoing treatment.
  • Participant has a significant cardiovascular or cerebrovascular disease, including a history of stroke within 12 months prior to screening.
  • Participant has any complicating systemic disease or active . Squamous cell carcinomas will be an exclusionary criterion if lesions are recurrent and/or > 2 cm in diameter and/or affect the lip or ear area. Basal cell carcinomas are permitted, provided they are not located in the immediate periocular facial region. A history of any prior malignancy is allowed if the treating physician or oncologist confirms that the participant has been free of recurrence or for at least 5 years prior to screening.
  • Participant has another known or suspected molecular diagnosis of macular or retinal disease (e.g., pathogenic mutations in other genes) that could confound interpretation of study outcomes, indicate a second concomitant retinal condition or suggest a different etiology for the macular disease.
  • Participant has evidence or history of choroidal neovascularization.
  • Participant has macular atrophy due to any cause other than a genetically or clinically confirmed diagnosis of STGD or STGD-like macular dystrophies.
  • Participant has a known diagnosis of any form of uncontrolled glaucoma (for high tension glaucoma IOP > 25 mmHg).
  • Participant has and/or is receiving treatment for thyroid eye disease.
  • Participant has diabetic retinopathy in excess of mild nonproliferative diabetic retinopathy (i.e., presents with widespread retinal microaneurysms, dot-blot hemorrhages, and cotton-wool retinal spots).
  • Participant has any other disease(s) affecting the optic nerve.
  • Participant has a history of anterior or posterior uveitis and/or presence of intraocular inflammation (≥ trace anterior chamber cell or flare), or history of idiopathic or autoimmune-associated uveitis in either eye. Note: A single, sporadic episode of anterior uveitis without recurrences in the past 5 years and not associated with chronic conditions that increase the likelihood of recurrence may be accepted on a case-by-case basis in consultation with the sponsor's medical monitor/lead.
  • Participant has corneal or lenticular opacities impeding the visualization of the fundus and/or the reliable performance of the visual function tests required by the protocol.
  • Participant has sufficiently narrow iridocorneal angles contraindicating pupillary dilation that have not been previously treated with preventative laser iridotomies.
  • Participant has any other ocular disorders that could interfere with or confound visual acuity and other ocular assessments, including OCT or FAF.
  • Participant has a epiretinal membrane or evidence of clinically significant vitreomacular traction syndrome. Note: A mild enhancement of the vitreoretinal interface seen on OCT without any alteration of the foveal profile would not be considered an exclusion criterion.
  • Participant has presence of or recurrent vitreous hemorrhages. Note: A one-time episode of a traumatic vitreous hemorrhage would not result in exclusion, so long as resolved.
  • Participant has aphakia.
  • Participant has anticipated need for cataract surgery during the study period.
  • Participant has a macular hole, evident by ophthalmoscopy and/or by SD-OCT examinations, or history of prior macular hole surgery.
  • Participant has a history of any of the following procedures: posterior vitrectomy, retinal detachment surgery, glaucoma filtering surgery (e.g., trabeculectomy), glaucoma drainage device implantation, selective laser trabeculoplasty, full-thickness or partial-thickness corneal transplant (e.g., Descemet's stripping endothelial keratoplasty, Descemet's stripping automated endothelial keratoplasty or Descemet's membrane endothelial keratoplasty).
  • Participant has any lesion that is considered to pose a risk of retinal detachment during the study. Any preexisting lesion may be treated to allow eligibility, but treatment must be completed at least 3 months prior to screening.
  • Participant has had any prior thermal laser or photodynamic therapy treatment in the macular region, regardless of indication. Peripheral retinal thermal laser treatments for holes, lattice degeneration, and/or other lesions with rhegmatogenous potential are permitted within 3 months prior to screening, subject to their potential impact on a future pars plana vitrectomy surgery.
  • Participant has had any intraocular surgery within 3 months of screening.
  • Participant has a history of intraocular metallic foreign bodies.
  • Participant has received (or plans to receive during the study) any treatment including gene therapy, stem cell therapy, surgical implantation of prosthetic retinal chips, or any prior intravitreal treatment for any indication in either eye that may be considered to potentially interfere with the study participation or its conduct.
  • Participant is receiving concomitant treatment with any ocular or systemic medication known to be toxic to the lens, retina or optic nerve.

    • Participant is using hydroxychloroquine (Plaquenil), chloroquine, pentosan polyphosphate (Elmiron), tamoxifen, chlorpromazine, thioridazine (Mellaril), isotretinoin (Accutane) or any related retina-toxic compounds at screening.
  • Participant has received (or plans to receive during the study) therapeutic radiation in the region of the study eye.
  • Participant has had (or plans to have during the study) any major surgical procedure within 1 month prior to screening or anticipates having one during the study, which may interrupt study participation.
  • Participant is taking glucagon-like peptide-1 (GLP-1) receptor agonists and is unable or unwilling to stop the medication at least 4 weeks prior to screening. A history of treatment with a GLP-1 receptor agonist is allowed.
  • Participant is taking metformin and is unable or unwilling to stop this medication at least 4 weeks prior to screening. A history of treatment with metformin is allowed.
  • Participant is participating (or plans to participate) in an interventional study of a vitamin A metabolism inhibitor, a vitamin A analog/derivative, or another drug product within 3 months prior to screening. After a 3 month , participants can be considered for enrollment. Participation in a noninterventional study (NIS) is allowed.
  • Participant has a known or suspected to eyedrops used for IOP measurement or pupil dilation.
  • Participant has any condition that makes the participant unsuitable for study participation.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
90 participants (estimated)
Patient registry
No

Groups and cohorts

  • Participants with Stargardt-type eye conditions

    Participants with STGD or STGD-like macular dystrophies.

    Other: No Intervention

Interventions

  • OtherNo Intervention

    No investigational drug will be administered to participants in this study.

06

What researchers measure

Primary outcomes

  1. Change from baseline in best corrected visual acuity (BCVA) at month 12

    BCVA will be measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letters chart.

    Time frame: Baseline and Month 12

Secondary outcomes

  1. Change from baseline in BCVA

    BCVA will be measured by ETDRS letters chart.

    Time frame: Baseline and Months 6, 18 and 24/Early Termination (ET)

  2. Change from baseline in low luminance visual acuity (LLVA)

    LLVA will be measured by ETDRS letters chart.

    Time frame: Baseline and Months 6, 12, 18 and 24/ET

  3. Change from baseline in Minnesota Reading Acuity Chart (MNREAD)

    MNREAD evaluates reading acuity, critical print size and maximum reading speed.

    Time frame: Baseline and Months 6, 12, 18 and 24/ET

  4. Change from baseline in mesopic MP sensitivity

    Defect-mapping, fundus-controlled microperimetry (MP) will be used to assess change in mesopic MP sensitivity.

    Time frame: Baseline and Months 6, 12, 18 and 24/ET

  5. Difference between eyes in change from baseline in BCVA

    BCVA will be measured by ETDRS letters chart.

    Time frame: Baseline and Months 6, 12, 18 and 24/ET

  6. Difference between eyes in change from baseline in LLVA

    LLVA will be measured by ETDRS letters chart.

    Time frame: Baseline and Months 6, 12, 18 and 24/ET

  7. Change from baseline in central retinal thickness (CRT)

    CRT will be measured by spectral-domain optical coherence tomography (SD-OCT).

    Time frame: Baseline and Months 6, 12, 18 and 24/ET

  8. Change from baseline in total photoreceptor thickness (TPT)

    TPT will be measured by SD-OCT.

    Time frame: Baseline and Months 6, 12, 18 and 24/ET

  9. Change from baseline in ellipsoid zone (EZ) integrity

    EZ integrity will be measured by SD-OCT.

    Time frame: Baseline and Months 6, 12, 18 and 24/ET

  10. Change from baseline in QDAF (Questionably Diminished Auto-Fluorescence)

    QDAF will be measured with Fundus Auto-Fluorescence (FAF).

    Time frame: Baseline and Months 6, 12, 18 and 24/ET

  11. Change from baseline in DDAF (Definitely Diminished Auto-Fluorescence)

    DDAF will be measured with FAF.

    Time frame: Baseline and Months 6, 12, 18 and 24/ET

  12. Difference between eyes in change from baseline in EZ integrity

    EZ integrity will be measured by SD-OCT.

    Time frame: Baseline and Months 6, 12, 18 and 24/ET

  13. Difference between eyes in change from baseline in CRT

    CRT will be measured by SD-OCT.

    Time frame: Baseline and Months 6, 12, 18 and 24/ET

  14. Difference between eyes in change from baseline in TPT

    TPT will be measured by SD-OCT.

    Time frame: Baseline and Months 6, 12, 18 and 24/ET

  15. Difference between eyes in change from baseline in QDAF

    QDAF will be measured by FAF.

    Time frame: Baseline and Months 6, 12, 18 and 24/ET

  16. Difference between eyes in change from baseline in DDAF

    DDAF will be measured by FAF.

    Time frame: Baseline and Months 6, 12, 18 and 24/ET

  17. Correlation between change from baseline in structural outcomes and functional outcomes

    Structural outcomes include: CRT, TPT, EZ integrity and FAF. Functional outcomes include: BCVA, LLVA, MNREAD parameters and mesopic MP sensitivity.

    Time frame: Baseline and Months 6, 12, 18 and 24/ET

  18. Longitudinal Association Between the Rate of Change in Structural and Functional Retinal Outcomes Assessed by Joint Modelling Analysis

    Change from baseline in structural outcomes (CRT, TPT, EZ Integrity) and functional outcomes (BCVA, Mesopic MP sensitivity) will be used for joint modelling analysis.

    Time frame: Baseline and Months 6, 12, 18 and 24/ET

  19. Rate of Disease Progression Over Time Associated with Structural and Functional Characteristics at Baseline

    Baseline characteristics: Genotype (ABCA4 vs non-ABCA4), BCVA, presence and size of central EZ, CRT and TPT, mesopic MP sensitivity. Rate of disease progression over time: Change from baseline in BCVA, EZ area, CRT, TPT, FAF and MP sensitivity.

    Time frame: Baseline and Months 6, 12, 18 and 24/ET

  20. Intraclass correlation coefficient at baseline (2 repeated measurements) in BCVA

    BCVA will be measured by ETDRS letters chart.

    Time frame: Baseline

  21. Intraclass correlation coefficient longitudinally between baseline and Month 12 in BCVA

    BCVA will be measured by ETDRS letters chart.

    Time frame: Baseline and Month 12

  22. Intraclass correlation coefficient at baseline (2 repeated measurements) in LLVA

    LLVA will be measured by ETDRS letters chart.

    Time frame: Baseline

  23. Intraclass correlation coefficient longitudinally between baseline and Month 12 in LLVA

    LLVA will be measured by ETDRS letters chart.

    Time frame: Baseline and Month 12

  24. Intraclass correlation coefficient at baseline (2 repeated measurements) in MNREAD parameters

    MNREAD evaluates reading acuity, critical print size and maximum reading speed.

    Time frame: Baseline

  25. Intraclass correlation coefficient longitudinally between baseline and Month 12 in MNREAD parameters

    MNREAD evaluates reading acuity, critical print size and maximum reading speed.

    Time frame: Baseline and Month 12

  26. Intraclass correlation coefficient at baseline (2 repeated measurements) in mesopic MP sensitivity

    MP will be used to assess mesopic sensitivity.

    Time frame: Baseline

  27. Intraclass correlation coefficient longitudinally between baseline and Month 12 in mesopic MP sensitivity

    MP will be used to assess mesopic sensitivity.

    Time frame: Baseline and Month 12

07

Study locations

15 of 15 sites recruiting
  • Associated Retina Consultants
    Phoenix, Arizona 85020, United States
    Recruiting
  • Stanford University School of Medicine
    Palo Alto, California 94303, United States
    Recruiting
  • University of California Health - UC Davis
    Sacramento, California 95817, United States
    Recruiting
  • University of Florida Health - UF Health Jacksonville
    Jacksonville, Florida 32209, United States
    Recruiting
  • University of Miami Health System - Bascom Palmer Eye Institute
    Miami, Florida 33136, United States
    Recruiting
  • University of Illinois Chicago - UI Health
    Chicago, Illinois 60612, United States
    Recruiting
  • University of Michigan Health - Kellogg Eye Center
    Ann Arbor, Michigan 48105, United States
    Recruiting
  • Deep Blue Retina
    Southaven, Mississippi 38671, United States
    Recruiting
  • Duke Eye Center
    Durham, North Carolina 27710, United States
    Recruiting
  • Cincinnati Eye Institute
    Cincinnati, Ohio 45242, United States
    Recruiting
  • Casey Eye Institute - Oregon Health & Science University
    Portland, Oregon 97239, United States
    Recruiting
  • Wills Eye Physicians - Mid Atlantic Retina
    Philadelphia, Pennsylvania 19107, United States
    Recruiting
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
    Recruiting
  • Retina Foundation of the Southwest
    Dallas, Texas 75231, United States
    Recruiting
  • University of Utah Health - John A Moran Eye Center
    Salt Lake City, Utah 84312, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Feb 2026 (actual). Primary completion is estimated for Dec 2028, 34 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Jul 2028 → Dec 2028 and completion Jul 2028 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2026
First posted
Feb 23, 2026
StartActual
Feb 20, 2026
Primary completionEst.
Dec 31, 2028was Jul 2028
CompletionEst.
Dec 31, 2028was Jul 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 31, 2028→Dec 31, 2028
Oct 20, 2026
Study completion
Jul 31, 2028→Dec 31, 2028
Oct 20, 2026
Show all 2 updates
  1. Nov 13, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 20, 2026
    Primary completion Jul 31, 2028→Dec 31, 2028
    Study completion Jul 31, 2028→Dec 31, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07425574
Responsible party
Sponsor
First posted
Feb 23, 2026
Start date
Feb 20, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 13, 2026

Study contacts

Astellas Pharma Global Development, Inc.
Contact
Astellas.registration@astellas.com
800-888-7704
Medical Director
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion